High Viral Suppression Found for Patients With HIV Receiving Long-Acting LEN/CAB
|
Among patients with HIV who received long-acting
LEN/CAB, those with baseline VS maintained it and those without achieved VS
by 13 weeks. |
HIV prevention drug hailed as breakthrough, but who gets access?
Lenacapavir, a twice-a-year injection could transform HIV prevention, but it will not be available to all. View article...